Suppr超能文献

使用二维超高效液相色谱-串联质谱法对基于替代基质的人脑脊液中β淀粉样蛋白42绝对定量方法的验证

Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry.

作者信息

Korecka Magdalena, Waligorska Teresa, Figurski Michal, Toledo Jon B, Arnold Steven E, Grossman Murray, Trojanowski John Q, Shaw Leslie M

机构信息

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Institute on Aging and Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

J Alzheimers Dis. 2014;41(2):441-51. doi: 10.3233/JAD-132489.

Abstract

The primary aims of this work were to: 1) establish a calibrator surrogate matrix for quantification of amyloid-β (Aβ)42 in human cerebrospinal fluid (CSF) and preparation of quality control samples for LC-MS-MS methodology, 2) validate analytical performance of the assay, and 3) evaluate its diagnostic utility and compare it with the AlzBio3 immunoassay. The analytical methodology was based on a 2D-UPLC-MS-MS platform. Sample pretreatment used 5 M guanidine hydrochloride and extraction on μElution SPE columns as previously described. A column cleaning procedure involved gradual removal of aqueous solvents by acetonitrile assured consistent long-term chromatography performance. Receiver-operator characteristic (ROC) curve and correlation analyses evaluated the diagnostic utility of UPLC-MS-MS compared to AlzBio3 immunoassay for detection of Alzheimer's disease (AD). The surrogate matrix, artificial CSF containing 4 mg/mL of BSA, provides linear and reproducible calibration comparable to human pooled CSF as calibration matrix. Appropriate cleaning of the trapping and analytical columns provided every-day, trouble-free runs. Analyses of CSF Aβ42 showed that UPLC-MS-MS distinguished neuropathologically-diagnosed AD subjects from healthy controls with at least equivalent diagnostic utility to AlzBio3. Comparison of ROC curves for these two assays showed no statistically significant difference (p = 0.2229). Linear regression analysis of Aβ42 concentrations measured by this mass spectrometry-based method compared to the AlzBio3 immunoassay showed significantly higher but highly correlated results. In conclusion, the newly established surrogate matrix for 2D-UPLC-MS-MS measurement of Aβ42 provides selective, reproducible, and accurate results. The documented analytical performance and diagnostic performance for AD versus controls supports consideration as a candidate reference method.

摘要

这项工作的主要目的是

1)建立用于定量人脑脊液(CSF)中淀粉样β蛋白(Aβ)42的校准替代基质,并制备用于液相色谱-串联质谱(LC-MS-MS)方法的质量控制样品;2)验证该检测方法的分析性能;3)评估其诊断效用,并将其与AlzBio3免疫分析方法进行比较。分析方法基于二维超高效液相色谱-串联质谱平台。样品预处理使用5M盐酸胍,并如前所述在μElution固相萃取柱上进行萃取。柱清洗程序包括通过乙腈逐步去除水性溶剂,以确保长期一致的色谱性能。接受者操作特征(ROC)曲线和相关性分析评估了与AlzBio3免疫分析相比,UPLC-MS-MS在检测阿尔茨海默病(AD)方面的诊断效用。替代基质,即含有4mg/mL牛血清白蛋白(BSA)的人工脑脊液,提供了与作为校准基质的人混合脑脊液相当的线性和可重复校准。对捕集柱和分析柱进行适当清洗可实现每日无故障运行。脑脊液Aβ42分析表明,UPLC-MS-MS能够将经神经病理学诊断的AD患者与健康对照区分开来,其诊断效用至少与AlzBio3相当。这两种检测方法的ROC曲线比较显示无统计学显著差异(p = 0.2229)。将基于这种质谱法测量的Aβ42浓度与AlzBio3免疫分析进行线性回归分析,结果显示前者显著更高但高度相关。总之,新建立的用于二维超高效液相色谱-串联质谱测量Aβ42的替代基质提供了选择性、可重复且准确的结果。所记录的针对AD与对照的分析性能和诊断性能支持将其视为候选参考方法进行考虑。

相似文献

2
Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS.
Clin Biochem. 2019 Oct;72:7-14. doi: 10.1016/j.clinbiochem.2019.05.006. Epub 2019 May 23.
4
Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry.
Alzheimers Dement. 2016 Jan;12(1):55-9. doi: 10.1016/j.jalz.2015.06.1890. Epub 2015 Jul 21.
6
An optimized UPLC-MS/MS method for human plasma amyloid-β 42 and 40 measurement and application in Alzheimer's disease diagnosis.
J Pharm Biomed Anal. 2024 Nov 15;250:116396. doi: 10.1016/j.jpba.2024.116396. Epub 2024 Aug 8.
9
Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease.
J Proteome Res. 2017 Mar 3;16(3):1228-1238. doi: 10.1021/acs.jproteome.6b00829. Epub 2017 Feb 7.
10
An UHPLC-MS/MS method for simultaneous quantification of human amyloid beta peptides Aβ1-38, Aβ1-40 and Aβ1-42 in cerebrospinal fluid using micro-elution solid phase extraction.
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Dec 1;1070:82-91. doi: 10.1016/j.jchromb.2017.10.047. Epub 2017 Oct 23.

引用本文的文献

2
Development of amyloid β (1-42) certified reference material NMIJ CRM 6210-a.
Anal Bioanal Chem. 2025 May;417(12):2679-2689. doi: 10.1007/s00216-025-05797-0. Epub 2025 Mar 5.
3
ADNI Biomarker Core: A review of progress since 2004 and future challenges.
Alzheimers Dement. 2025 Jan;21(1):e14264. doi: 10.1002/alz.14264. Epub 2024 Nov 30.
4
Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity.
Neurology. 2024 Jul 9;103(1):e209419. doi: 10.1212/WNL.0000000000209419. Epub 2024 Jun 11.
5
Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology.
Mol Neurodegener. 2024 May 18;19(1):41. doi: 10.1186/s13024-024-00727-7.
7
An LC-MS/MS-based platform for the quantification of multiple amyloid beta peptides in surrogate cerebrospinal fluid.
J Mass Spectrom Adv Clin Lab. 2024 Jan 22;31:40-48. doi: 10.1016/j.jmsacl.2024.01.002. eCollection 2024 Jan.
8
Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry.
Mol Cell Proteomics. 2024 Feb;23(2):100721. doi: 10.1016/j.mcpro.2024.100721. Epub 2024 Jan 20.
9
Comparing Symmetric Dimethylarginine and Amyloid-β42 as Predictors of Alzheimer's Disease Development.
J Alzheimers Dis Rep. 2023 Dec 29;7(1):1427-1444. doi: 10.3233/ADR-230054. eCollection 2023.
10
Harmonization and standardization of biofluid-based biomarker measurements for AT(N) classification in Alzheimer's disease.
Alzheimers Dement (Amst). 2023 Aug 16;15(3):e12465. doi: 10.1002/dad2.12465. eCollection 2023 Jul-Sep.

本文引用的文献

1
A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.
Alzheimers Dement. 2014 Jul;10(4):477-484.e1. doi: 10.1016/j.jalz.2013.06.003. Epub 2013 Aug 24.
2
Monetary costs of dementia in the United States.
N Engl J Med. 2013 Apr 4;368(14):1326-34. doi: 10.1056/NEJMsa1204629.
4
Alzheimer disease in the United States (2010-2050) estimated using the 2010 census.
Neurology. 2013 May 7;80(19):1778-83. doi: 10.1212/WNL.0b013e31828726f5. Epub 2013 Feb 6.
7
Preparation and extraction of insoluble (inclusion-body) proteins from Escherichia coli.
Curr Protoc Protein Sci. 2012 Nov;Chapter 6:6.3.1-6.3.20. doi: 10.1002/0471140864.ps0603s70.
10
CSF biomarkers cutoffs: the importance of coincident neuropathological diseases.
Acta Neuropathol. 2012 Jul;124(1):23-35. doi: 10.1007/s00401-012-0983-7. Epub 2012 Apr 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验